Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Peringkat dalam Saham
#4951
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Harga Saham
$2.47
Kapitalisasi Pasar
$2.95B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-14.68%
Negara
CN
Perdagangan Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategori
Healthcare
Laba untuk Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Laba pada Jun 2026 TTM: $450.70M
Menurut laporan keuangan terbaru dari Jilin Aodong Pharmaceutical Group Co., Ltd., laba saat ini perusahaan adalah $450.70M. Pada tahun 2023, perusahaan memperoleh laba sebesar $211.93M, penurunan dibandingkan dengan laba tahun 2022 sebesar $249.47M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Jilin Aodong Pharmaceutical Group Co., Ltd. dari 2000 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $450.70M | 116.23% |
| 2024 | $208.44M | -1.65% |
| 2023 | $211.93M | -15.05% |
| 2022 | $249.47M | -10.25% |
| 2021 | $277.96M | 5.78% |
| 2020 | $262.76M | 23.65% |
| 2019 | $212.51M | 47.80% |
| 2018 | $143.78M | -51.61% |
| 2017 | $297.11M | 18.54% |
| 2016 | $250.63M | -39.05% |
| 2015 | $411.21M | 71.49% |
| 2014 | $239.79M | 22.14% |
| 2013 | $196.32M | 79.35% |
| 2012 | $109.46M | -71.97% |
| 2011 | $390.52M | 99.92% |
| 2010 | $195.34M | -5.51% |
| 2009 | $206.72M | 55.20% |
| 2008 | $133.20M | -52.18% |
| 2007 | $278.56M | 315.81% |
| 2006 | $66.99M | 289.48% |
| 2005 | $17.20M | -21.22% |
| 2004 | $21.83M | 20.73% |
| 2003 | $18.09M | 43.68% |
| 2002 | $12.59M | 67.81% |
| 2001 | $7.50M | -36.78% |
| 2000 | $11.87M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 291.51% |
IN
|
